Status:
COMPLETED
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
Lead Sponsor:
Amgen
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.
Eligibility Criteria
Inclusion
- Breast cancer diagnosis node-positive or high risk node negative
- Estrogen receptor (ER) negative or ER positive (stage IIA, IIB or IIIA) disease.
Exclusion
- Metastatic breast cancer
- Clinically significant cardiac disease
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00261313
Start Date
December 1 2005
End Date
December 1 2007
Last Update
February 26 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.